Sjuts Dustin S 4
4 · Revance Therapeutics, Inc. · Filed Jul 5, 2022
Insider Transaction Report
Form 4
Sjuts Dustin S
Chief Commercial Officer
Transactions
- Award
Common Stock
2022-06-30$11.75/sh+1,000$11,747→ 98,123 total
Footnotes (1)
- [F1]These shares were acquired by Mr. Sjuts under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2022 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).